Compare TBPH & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | SDGR |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | United States |
| Employees | N/A | 850 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.9M | 850.5M |
| IPO Year | 2013 | 2020 |
| Metric | TBPH | SDGR |
|---|---|---|
| Price | $16.45 | $11.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $18.40 | ★ $21.13 |
| AVG Volume (30 Days) | 528.6K | ★ 907.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | 45.14 |
| EPS | ★ 2.06 | N/A |
| Revenue | $15,386,000.00 | ★ $255,869,000.00 |
| Revenue This Year | $1.04 | $1.20 |
| Revenue Next Year | N/A | $4.36 |
| P/E Ratio | $8.05 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $8.12 | $10.95 |
| 52 Week High | $21.03 | $27.63 |
| Indicator | TBPH | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 39.73 |
| Support Level | $13.41 | $11.03 |
| Resistance Level | $19.04 | $13.36 |
| Average True Range (ATR) | 0.53 | 0.47 |
| MACD | 0.37 | 0.03 |
| Stochastic Oscillator | 99.04 | 27.95 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.